22138-45-0

Basic information

• Product Name: (S)-3-hydroxybutyryl-Coenzyme A
• Synonyms: (S)-3-hydroxybutyryl-Coenzyme A
• CAS NO: 22138-45-0
• Molecular Weight: 853.632
• Mol File: 22138-45-0.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (S)-3-hydroxybutyryl-Coenzyme A(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-hydroxybutyryl-Coenzyme A(22138-45-0)
• EPA Substance Registry System: (S)-3-hydroxybutyryl-Coenzyme A(22138-45-0)

Safety Data

• Hazardous Substances Data: 22138-45-0(Hazardous Substances Data)

Upstream product

• 85-61-0 coenzyme A 
• 300-85-6 3-Hydroxybutyric acid 
• 56-65-5 ATP 
• 1420-36-6 acetoacetyl coenzyme A 
• 1383119-39-8 2-hydroxyisobutyryl-CoA 
• 75-07-0 acetaldehyde 
• 524-14-1 S-(hydrogen malonyl)coenzyme A 
• 727388-72-9 3-hydroxybutyrate thiophenyl ester 

Downstream Products

• 1420-36-6 acetoacetyl coenzyme A 

Relevant articles and documents

Identification of an α-Oxoamine Synthase and a One-Pot Two-Step Enzymatic Synthesis of α-Amino Ketones

Alb29, an α-oxoamine synthase involved in albogrisin biosynthesis in Streptomyces albogriseolus MGR072, was characterized and responsible for the incorporation of l-glutamate to acyl-coenzyme A substrates. Combined with Alb29 and Mgr36 (an acyl-coenzyme A ligase), a one-pot enzymatic system was established to synthesize seven α-amino ketones. When these α-amino ketones were fed into the alb29 knockout strain Δalb29, respectively, the albogrisin analogs with different side chains were observed.

A FabG inhibitor targeting an allosteric binding site inhibits several orthologs from Gram-negative ESKAPE pathogens

The spread of antibiotic resistance within the ESKAPE group of human pathogenic bacteria poses severe challenges in the treatment of infections and maintenance of safe hospital environments. This motivates efforts to validate novel target proteins within these species that could be pursued as potential targets for antibiotic development. Genetic data suggest that the enzyme FabG, which is part of the bacterial fatty acid biosynthetic system FAS-II, is essential in several ESKAPE pathogens. FabG catalyzes the NADPH dependent reduction of 3-keto-acyl-ACP during fatty acid elongation, thus enabling lipid supply for production and maintenance of the cell envelope. Here we report on small-molecule screening on the FabG enzymes from A. baumannii and S. typhimurium to identify a set of μM inhibitors, with the most potent representative (1) demonstrating activity against six FabG-orthologues. A co-crystal structure with FabG from A. baumannii (PDB:6T65) confirms inhibitor binding at an allosteric site located in the subunit interface, as previously demonstrated for other sub-μM inhibitors of FabG from P. aeruginosa. We show that inhibitor binding distorts the oligomerization interface in the FabG tetramer and displaces crucial residues involved in the interaction with the co-substrate NADPH. These observations suggest a conserved allosteric site across the FabG family, which can be potentially targeted for interference with fatty acid biosynthesis in clinically relevant ESKAPE pathogens.

Chemoenzymatic Synthesis of Acyl Coenzyme A Substrates Enables in Situ Labeling of Small Molecules and Proteins

A chemoenzymatic approach to generate fully functional acyl coenzyme A molecules that are then used as substrates to drive in situ acyl transfer reactions is described. Mass spectrometry based assays to verify the identity of acyl coenzyme A enzymatic products are also illustrated. The approach is responsive to a diverse array of carboxylic acids that can be elaborated to their corresponding coenzyme A thioesters, with potential applications in wide-ranging chemical biology studies that utilize acyl coenzyme A substrates.